Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report report published on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $1.00 target price on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $1.60 price objective on shares of Akari Therapeutics in a research report on Tuesday, September 9th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $2.53.

Akari Therapeutics Stock Performance

NASDAQ:AKTX opened at $0.29 on Monday. Akari Therapeutics has a twelve month low of $0.22 and a twelve month high of $1.73. The company has a 50-day moving average of $0.42 and a 200-day moving average of $0.77.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Cresset Asset Management LLC boosted its position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 4,368.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 822,468 shares of the biopharmaceutical company’s stock after purchasing an additional 804,060 shares during the period. Cresset Asset Management LLC owned 2.52% of Akari Therapeutics worth $831,000 at the end of the most recent reporting period. 5.06% of the stock is owned by institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.